Unknown

Dataset Information

0

Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors.


ABSTRACT: Fungal infections and drug-resistance are rapidly increasing with the deterioration of the external environment. Squalene cyclooxygenase (SE) and 14α-demethylase (CYP51) are considered to be important antifungal targets, and the corresponding pharmacophore models can be used to design and guide the discovery of novel inhibitors. Therefore, the common feature pharmacophore model (SE inhibitor) and structure-based pharmacophore model (CYP51 receptor) were constructed using different methods in this study. Then, appropriate organic fragments were selected and superimposed onto the pharmacophore features, and compounds 5, 6 and 8 were designed and produced by linking these organic fragments. It is noteworthy that compound 8 can simultaneously match the features of both the SE and CYP51 pharmacophores. Further analysis found that these compounds exhibit a potent antifungal activity. Preliminary mechanistic studies revealed that compound 8 could undergo dual-target inhibition (SE and CYP51) of Candida albicans. This study proved the rationale of pharmacophore models (SE and CYP51), which can guide the design and discovery of new antifungal inhibitors.

SUBMITTER: Dong Y 

PROVIDER: S-EPMC9070380 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors.

Dong Yue Y   Liu Min M   Wang Jian J   Ding Zhuang Z   Sun Bin B  

RSC advances 20190822 45


Fungal infections and drug-resistance are rapidly increasing with the deterioration of the external environment. Squalene cyclooxygenase (SE) and 14α-demethylase (CYP51) are considered to be important antifungal targets, and the corresponding pharmacophore models can be used to design and guide the discovery of novel inhibitors. Therefore, the common feature pharmacophore model (SE inhibitor) and structure-based pharmacophore model (CYP51 receptor) were constructed using different methods in thi  ...[more]

Similar Datasets

| S-EPMC6072327 | biostudies-literature
| S-EPMC7294727 | biostudies-literature
| S-EPMC4094703 | biostudies-literature
| S-EPMC4018153 | biostudies-literature
| S-EPMC10863211 | biostudies-literature
| S-EPMC11894060 | biostudies-literature
| S-EPMC4025812 | biostudies-literature
| S-EPMC4393062 | biostudies-literature
| S-EPMC8002023 | biostudies-literature
| S-EPMC3691235 | biostudies-literature